Reference - Detail
|Author||Mera H, Kawashima H, Yoshizawa T, Ishibashi O, Ali MM, Hayami T, Kitahara H, Yamagiwa H, Kondo N, Ogose A, Endo N, Kawashima H.|
|Title||Chondromodulin-1 directly suppresses growth of human cancer cells.|
BACKGROUND:Chondromodulin-1 (ChM1), an endogenous anti-angiogenic factor expressed in cartilage, has been suggested to inhibit invasion of endothelial cells into cartilage. In addition, the ectopic administration of ChM1 has been reported to suppress tumorigenesis in vivo. However, it is unclear whether the anti-tumor effect is due to not only the anti-vascularization effect of ChM1, but also its direct action against oncocytes. In the present study, we sought to determine whether ChM1 has a direct action on tumor cells.
METHODS:BrdU incorporation assay was performed on human umbilical vein endothelial cells (HUVECs), normal human dermal fibroblasts (NHDFs), HepG2 cells and HeLa cells in the presence or absence of recombinant human ChM1 (rhChM1). An adenovirus that expresses ChM1, Ad-ChM1, was established and applied to the tumor xenografted in vivo, and to in vitro tumor cells cultured on plates or in soft agar. Cell cycle-related proteins and the phosphorylation of Erk, Akt, and GSK3beta, the downstream molecules of the extracellular matrix-integrin signaling pathways, in HepG2 cells treated with or without Ad-ChM1 were detected by western blot analysis. Luciferase reporter assays of STAT, GAS, and ISRE, which participate in another cytokine signaling pathway, ware performed in HepG2, HeLa, and HUVEC cells.
RESULTS:ChM1 suppressed BrdU incorporation in HUVECs and in HepG2 cells dose-dependently, but did not suppress BrdU incorporation in NHDFs and HeLa cells cultured on plates. In soft agar, however, ChM1 suppressed the growth of HeLa cells, as well as HepG2 cells. Western blot analyses demonstrated that ChM1 decreased the levels of cyclin D1, cyclin D3, and cdk6 and increased those of p21cip1 without affecting the phosphorylation levels of Erk, Akt, and GSK3beta in HepG2 cells. The luciferase reporter assay demonstrated that ChM1 suppressed the transcriptional activities of STAT and GAS but not of ISRE.
CONCLUSION:ChM1 directly suppressed the proliferation of tumor cells in an anchorage-independent manner. However, ChM1 did not alter the phosphorylation of downstream molecules, at which the signaling pathways through growth factor and cytokine receptors converge with the anchorage-dependent pathway. Our results show that ChM1 has a direct anti-tumor effect; moreover, this effect occurs by inhibiting the STAT signaling pathway.
|MeSH||Adenoviridae / genetics Animals Carcinoma, Hepatocellular / genetics Carcinoma, Hepatocellular / metabolism Carcinoma, Hepatocellular / pathology Carcinoma, Hepatocellular / therapy Cell Cycle Proteins / biosynthesis Cell Line, Tumor DNA, Neoplasm / antagonists & inhibitors DNA, Neoplasm / biosynthesis Endothelial Cells / cytology Endothelial Cells / drug effects Endothelial Cells / metabolism Genetic Vectors / genetics HeLa Cells Humans Intercellular Signaling Peptides and Proteins / biosynthesis* Intercellular Signaling Peptides and Proteins / genetics Liver Neoplasms / genetics Liver Neoplasms / metabolism Liver Neoplasms / pathology Liver Neoplasms / therapy Male Membrane Proteins / biosynthesis* Membrane Proteins / genetics Mice Mice, Inbred BALB C Mice, Nude Neoplasms / genetics Neoplasms / metabolism Neoplasms / pathology Neoplasms / therapy* Prostatic Neoplasms / genetics Prostatic Neoplasms / metabolism Prostatic Neoplasms / pathology Prostatic Neoplasms / therapy Recombinant Proteins / biosynthesis Recombinant Proteins / genetics STAT Transcription Factors / metabolism Signal Transduction / drug effects Transfection|
|DNA material||pSTAT RE-TK hRluc(F) (RDB05616) pISRE-TK hRluc(F) (RDB05610) pGAS RE-TK hRluc(F) (RDB05624).|